

## Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated *NPM1* and *FLT3-ITD*

Hendrik J.M. de Jonge,<sup>1\*</sup> Peter J.M. Valk,<sup>2\*</sup> Eveline S.J.M. de Bont,<sup>1</sup> Jan Jacob Schuringa,<sup>3</sup> Gert Ossenkoppele,<sup>4</sup> Edo Vellenga,<sup>3</sup> and Gerwin Huls<sup>3</sup>

<sup>1</sup>Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, the Netherlands, <sup>2</sup>Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands, <sup>3</sup>Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands, and <sup>4</sup>Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Citation: de Jonge HJM, Valk PJM, de Bont ESJM, Schuringa JJ, Ossenkoppele G, Vellenga E, and Huls G. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated *NPM1* and *FLT3-ITD*. *Haematologica* 2011;96(9):1310-1317. doi:10.3324/haematol.2011.040592

**Online Supplementary Figure S1.** Impact of WBC count on event-free survival (EFS) and overall survival (OS) within all AML cases and within AML cases with favorable, intermediate and unfavorable risk cytogenetics. (A) EFS according to WBC count in all 525 AML case, (B) OS for this group (C) EFS according to WBC count in 331 AML cases with intermediate risk cytogenetics, (D) OS for this group. (E) EFS according to WBC count in 89 AML cases with favorable risk cytogeneticis, (F) OS for this group (G) EFS according to WBC count in 85 AML cases with unfavorable risk cytogenetics, (H) OS for this group. P value is given for the overall comparison across all three groups.



